FDA
-
-
-
-
-
-
-
Immunomedics (IMMU) Announces FDA Orphan Drug Designation of Trodelvy for Adult and Pediatric Glioblastoma
-
-
-
-
-
-
-
Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
-
-
-
-
-
-
-
Gilead Sciences (GILD) to Acquire Immunomedics (IMMU) for $21 Billion
-
-
-
-
-
-
-
Immunomedics Announces FDA Approval of Samsung Biologics as Antibody Manufacturer for Trodelvy™
-
-
-
-
-
-
-
Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers
-
-
-
-
-
-
-
Immunomedics to Participate in Upcoming Healthcare Conferences
-
-
-
-
-
-
-
Immunomedics to Present New Trodelvy™ Data In Non-Breast Cancer Indications at the 2020 ASCO Virtual Meeting
-
251,890 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All